Skip to content
CityAM
Main navigation
  • News
    • News
      • Latest Business News
      • Economics
      • Politics
      • Tech
      • Banking
      • FTSE 100 Live
      • Retail
      • Insurance
      • Legal
      • Property
      • Transport
      • Markets
    • From our partners
      • AON
      • Bayes Business School
      • Canada BIDs
      • Central London Alliance CIC
      • Destination City
      • Halkin
      • Olympia
      • Inside Saudi
      • Tottenham Hotspur Stadium
      • Santander X
      • YEAR SIX Dividend
    • Featured

      A decade after Brexit, what does the City want next?

      European Business Alliance meeting discussing economic growth strategies, with diverse leaders engaging in a roundtable di...

      Submit a story

      Tell us your story.

      Submit
  • Opinion
  • Sport
    • Latest Sports News
      • Sport
      • Sport Business
    • From our partners
      • The Morning Briefing: SBS x CityAM
      • Aramco Team Series
      • LIV Golf
    • Featured

      Advertising at World Cup: Levi’s genius, hydration breaks and dodging rules

      Breaking news event with diverse crowd gathered outside urban office building on sunny day, capturing vibrant city life.

      Submit a story

      Tell us your story.

      Submit
  • Life&Style
    • Life&Style
      • Life&Style
      • Toast the City Awards
      • The Magazine
      • Travel
      • Culture
      • Motoring
      • Wellness
      • The RED BULLETiN
      • Do it with Shared Ownership
      • Media Speak Hub
    • Featured

      Procter & Gamble axes relationship with Kremlin propaganda channel

      007 PG news article image featuring a business meeting with executives discussing strategy at a modern conference table

      Submit a story

      Tell us your story.

      Submit
  • Investec
  • Events
  • Latest Paper
Tuesday 09 April 2019 8:29 am  |  Updated:  Monday 03 June 2019 1:42 am

The UK’s drug policy is falling behind the rest of the world

By: Katherine Denham

Add as a preferred source on Google

Every year, thousands of people die as a result of drug misuse in the UK. And for over two decades, heroin has been the main culprit.

Communities are blighted, families are ripped apart, and vulnerable people are failed by an outdated approach.

The situation in Scotland is particularly dire, with a fifth of the UK’s drug-related deaths happening there in 2017. It’s a drug death rate nearly 50 times larger than Portugal’s.

We desperately need a new direction. One of the most prominent proposals is to trial drug consumption rooms (DCRs), which allow people who use illicit drugs to do so within a medically supervised environment.

Much like the rest of our drug policy, the UK is falling behind the rest of the world in failing to even trial this proven harm-reduction approach. Germany, France, Canada, Australia and many other countries operate multiple DCRs that successfully engage marginalised drug users with clean needles, medical care and treatment referral.

In a new paper, the Adam Smith Institute argues that the international evidence is clear; these facilities reduce drug-related deaths, relieve health burdens, and decrease public injection and syringe litter.

Crucially, there are no recorded overdose deaths in a drug consumption room. With trained staff on hand to administer oxygen and naloxone (a medicine used to reverse the effects of opioid overdoses), DCRs save lives.

Integrating them with allied services can also improve marginalised people’s access to counselling, medical testing, psychosocial, housing and employment services.

Local authorities and MPs who are tired of stagnant progress in reducing drug-related harms in their constituencies have been pushing for change, but the government and the Home Office have thus far refused to listen.

Our failure to engage vulnerable users is also exacerbating issues associated with illicit drug use, such as mental health problems and rough sleeping.

Yet despite a clear endorsement from the ACMD and the Home Office, accepting the public health case for DCRs, they still sit in a legal grey zone, leading to a lack of willingness by local authorities to trial them.

Nonetheless, there is some cause for optimism.

Last month, the Home Office gave the green light to the UK’s first licensed drug testing service, following years of reluctance.

The Labour Party announced its support for trialling DCRs earlier this month, and at least 10 chief constables support plans to open DCRs in their areas. A private members’ bill to establish a legal framework for these facilities is due to be debated in parliament, and enjoys cross-party support.

But political opposition to DCRs – often based on personal convictions rather than hard evidence – remains strong.

The fantastical idea that a marginally less miserable life for drug users might attract otherwise reluctant people to cultivate a heroin addiction is also groundless

The starkest illustration of this sentiment, shared by some politicians, comes from arch-prohibitionist Peter Hitchens, who has argued that “the nicer we are to drug users, the more of them there will be”. In the short-term, he’s absolutely right. Shockingly, if fewer heroin addicts are dying, there will obviously be more heroin addicts.

But engaging hard-to-reach populations in recovery services through DCRs has the potential to reduce addiction in the long-run.

Illicit drug users are more likely to kick the habit if they actually walk through the door of a facility that offers referrals to treatment.

The fantastical idea that a marginally less miserable life for drug users might attract otherwise reluctant people to cultivate a heroin addiction is also groundless. In fact, a recent systematic review of the evidence found no evidence that DCRs increase drug use, trafficking, or crime in their areas of operation.

Residents in areas of DCR operation must be continually involved in any planning process. Experience in other countries suggests that local communities appreciate the benefits of these schemes, such as reductions in public injecting and associated litter.

Given the choice between uncontrolled drug use on nearby streets or in a supervised, legal facility, most businesses and local residents can be persuaded to opt for the latter.

I live a few minutes walk away from an admirable drug and alcohol service in Camberwell – an area of London particularly struggling with drug-related crime – and not finding discarded needles on my morning walk to the bus stop would certainly make me feel more comfortable.

With the right approach and proper engagement among stakeholders, many communities suffering the consequences of illicit drug use would greatly benefit from a drug consumption room.

There’s growing momentum among politicians, police forces, public health experts, harm reduction charities, and many other campaigners to trial such schemes.

Keep up the pressure, and they might just force the government into a rethink. Many lives depend on this happening sooner rather than later.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Markets & Economics
  • News
  • Opinion

Categories

  • Business
  • Economics
  • Opinion
  • Politics

Related Topics

Trending Articles

  • Who could be Andy Burnham’s Chancellor? 

  • As it happened: Stocks recover after markets rocked by tech-sell off; US claims ‘good foundations’ of Iran deal

  • As it happened: FTSE 100 finishes higher as US-Iran talks progress and Starmer resigns; Space X shares fall after bond sale

  • Coca-Cola brings in restructuring lineup over failed Costa sale

  • Reeves’ new tax charge on cash ISAs faces fierce industry backlash

More from CityAM

  • Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

    Business Wire
  • Regulator wins decade-long pricing tussle with Pfizer

    Legal
    Hikma reported a jump in profit for 2024
  • City trader: ‘My coke dealer came to the Canary Wharf office every day at 9am’

    Video
    Skyline of Canada financial district with modern skyscrapers and historic landmarks under a clear blue sky
  • GSK says AI is reshaping drug pipeline as Nuvalent deal hits shares

    Tech
    GSK said total sales fell by two per cent in the third quarter
  • GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn

    Pharma
    GSK logo displayed prominently, signifying the companys presence and relevance in the business and healthcare sectors.
  • Boots eyes £7.5bn sale in blow to hopes of London IPO

    Retail
    Boots remains one of the group’s best performing business lines, with a London float suggested as recently as last year. (Photo by Oli Scarff/Getty Images)
  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

    Business Wire
  • British American Tobacco shares slide as cigarette volumes decline

    Business
    British American Tobacco headquarters with falling stock prices graph, reflecting decline in cigarette volumes and share p...

CityAM Canada — business, markets and opinion for Canadian readers.

Sections

  • Business
  • Markets
  • Tech
  • AI
  • Economics
  • Opinion
  • Cities

Company

  • About
  • Contact

Legal

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 CityAM Canada. All rights reserved.
Terms · Privacy · Cookies